Logo image of RXRX

RECURSION PHARMACEUTICALS-A (RXRX) Stock Fundamental Analysis

NASDAQ:RXRX - Nasdaq - US75629V1044 - Common Stock - Currency: USD

4.92  -0.25 (-4.84%)

After market: 4.93 +0.01 (+0.2%)

Fundamental Rating

2

RXRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. RXRX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, RXRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RXRX has reported negative net income.
RXRX had a negative operating cash flow in the past year.
In the past 5 years RXRX always reported negative net income.
In the past 5 years RXRX always reported negative operating cash flow.
RXRX Yearly Net Income VS EBIT VS OCF VS FCFRXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

RXRX's Return On Assets of -44.04% is in line compared to the rest of the industry. RXRX outperforms 54.38% of its industry peers.
RXRX has a Return On Equity (-61.54%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -44.04%
ROE -61.54%
ROIC N/A
ROA(3y)-38.78%
ROA(5y)-35.21%
ROE(3y)-54.96%
ROE(5y)-47.04%
ROIC(3y)N/A
ROIC(5y)N/A
RXRX Yearly ROA, ROE, ROICRXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

With a decent Gross Margin value of 6.50%, RXRX is doing good in the industry, outperforming 72.63% of the companies in the same industry.
RXRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 6.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RXRX Yearly Profit, Operating, Gross MarginsRXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

3

2. Health

2.1 Basic Checks

RXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RXRX has been increased compared to 1 year ago.
RXRX has more shares outstanding than it did 5 years ago.
RXRX has a worse debt/assets ratio than last year.
RXRX Yearly Shares OutstandingRXRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
RXRX Yearly Total Debt VS Total AssetsRXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

RXRX has an Altman-Z score of 0.48. This is a bad value and indicates that RXRX is not financially healthy and even has some risk of bankruptcy.
RXRX's Altman-Z score of 0.48 is fine compared to the rest of the industry. RXRX outperforms 65.30% of its industry peers.
RXRX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
RXRX has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 0.48
ROIC/WACCN/A
WACC15.92%
RXRX Yearly LT Debt VS Equity VS FCFRXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

RXRX has a Current Ratio of 4.11. This indicates that RXRX is financially healthy and has no problem in meeting its short term obligations.
RXRX has a Current ratio (4.11) which is in line with its industry peers.
RXRX has a Quick Ratio of 4.11. This indicates that RXRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RXRX (4.11) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.11
Quick Ratio 4.11
RXRX Yearly Current Assets VS Current LiabilitesRXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for RXRX have decreased by -9.26% in the last year.
Looking at the last year, RXRX shows a very strong growth in Revenue. The Revenue has grown by 29.32%.
The Revenue has been growing by 90.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-9.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.21%
Revenue 1Y (TTM)29.32%
Revenue growth 3Y79.46%
Revenue growth 5Y90.91%
Sales Q2Q%6.89%

3.2 Future

Based on estimates for the next years, RXRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.54% on average per year.
The Revenue is expected to grow by 60.30% on average over the next years. This is a very strong growth
EPS Next Y10.08%
EPS Next 2Y6.38%
EPS Next 3Y15.54%
EPS Next 5YN/A
Revenue Next Year8.6%
Revenue Next 2Y29.48%
Revenue Next 3Y60.3%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RXRX Yearly Revenue VS EstimatesRXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
RXRX Yearly EPS VS EstimatesRXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RXRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXRX Price Earnings VS Forward Price EarningsRXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXRX Per share dataRXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as RXRX's earnings are expected to grow with 15.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.38%
EPS Next 3Y15.54%

More info and screens

0

5. Dividend

5.1 Amount

RXRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RECURSION PHARMACEUTICALS-A

NASDAQ:RXRX (6/13/2025, 8:00:02 PM)

After market: 4.93 +0.01 (+0.2%)

4.92

-0.25 (-4.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-06 2025-08-06/amc
Inst Owners73.92%
Inst Owner Change0.77%
Ins Owners2.74%
Ins Owner Change3.75%
Market Cap2.00B
Analysts72.86
Price Target7.14 (45.12%)
Short Float %27.47%
Short Ratio4.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.87%
Min EPS beat(2)-20.37%
Max EPS beat(2)6.63%
EPS beat(4)3
Avg EPS beat(4)-1.86%
Min EPS beat(4)-20.37%
Max EPS beat(4)6.63%
EPS beat(8)6
Avg EPS beat(8)0.18%
EPS beat(12)9
Avg EPS beat(12)0.85%
EPS beat(16)10
Avg EPS beat(16)-28.95%
Revenue beat(2)0
Avg Revenue beat(2)-48.49%
Min Revenue beat(2)-76.78%
Max Revenue beat(2)-20.21%
Revenue beat(4)1
Avg Revenue beat(4)-26.17%
Min Revenue beat(4)-76.78%
Max Revenue beat(4)6.62%
Revenue beat(8)2
Avg Revenue beat(8)-21.8%
Revenue beat(12)4
Avg Revenue beat(12)-9.33%
Revenue beat(16)4
Avg Revenue beat(16)-17.58%
PT rev (1m)-10.64%
PT rev (3m)-20.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)28.79%
EPS NY rev (1m)0%
EPS NY rev (3m)14.14%
Revenue NQ rev (1m)-6.88%
Revenue NQ rev (3m)-17.94%
Revenue NY rev (1m)-4.76%
Revenue NY rev (3m)-19.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 33.45
P/FCF N/A
P/OCF N/A
P/B 2.14
P/tB 4.54
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0.15
BVpS2.3
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.04%
ROE -61.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 6.5%
FCFM N/A
ROA(3y)-38.78%
ROA(5y)-35.21%
ROE(3y)-54.96%
ROE(5y)-47.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.32%
Cap/Sales 14.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.11
Quick Ratio 4.11
Altman-Z 0.48
F-Score2
WACC15.92%
ROIC/WACCN/A
Cap/Depr(3y)133.89%
Cap/Depr(5y)201.24%
Cap/Sales(3y)47.71%
Cap/Sales(5y)136.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.21%
EPS Next Y10.08%
EPS Next 2Y6.38%
EPS Next 3Y15.54%
EPS Next 5YN/A
Revenue 1Y (TTM)29.32%
Revenue growth 3Y79.46%
Revenue growth 5Y90.91%
Sales Q2Q%6.89%
Revenue Next Year8.6%
Revenue Next 2Y29.48%
Revenue Next 3Y60.3%
Revenue Next 5YN/A
EBIT growth 1Y-52.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.65%
EBIT Next 3Y-2.85%
EBIT Next 5YN/A
FCF growth 1Y-46.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66%
OCF growth 3YN/A
OCF growth 5YN/A